U.S. healthcare policy is undergoing rapid change, with wide-ranging consequences for biopharma strategy, pricing, and competitiveness. From government efforts to control drug costs to shifts in vaccine policy to PBM reform, manufacturers face a complex and evolving policy landscape. At the same time, evolving trade policies have created a climate of uncertainty for biopharma companies, making it difficult to manage supply chains and make long-term plans.
Join Sara Mallatt, Director of Healthcare Research at AlphaSense, and Dr. Robert Popovian, Vice President, Health Economics and Policy at Equideum Health, on October 22nd as they break down the policy developments that matter most for biopharma leaders—what’s changing, how it may impact the industry, and the strategies companies are deploying to adapt.